,i  #aadth ,,congress  #ast ,session    
,h4 ,r4 #biba  ,,in ,,the ,,house ,,of  
,,representatives  ,june #be1 #bjae ,mr4
 ,forbes 7for himself and ,mr4          
,lipinski7 introduced the following     
bill2 which was referred to the         
,committee on ,energy and ,commerce  ,a 
,,bill  ,to intensify stem cell research
 showing evidence of substantial        
clinical benefit to patients1 and for   
other purposes4  #a4 ,short title ,this 
,act may be cited as the ,patients      
,first ,act of #bjae4  #b4 ,purposes ,it
 is the purpose of this ,act to--  7#a7 
intensify research that may result in   
improved understanding of or treatments 
for diseases and other adverse health   
conditions2  7#b7 promote research and  
human clinical trials using stem cells  
that are ethically obtained and show    
evidence of providing clinical benefit  
for human patients2 and  7#c7 promote   
the derivation of pluripotent stem cell 
lines without the creation of human     
embryos for research purposes and       

without the destruction or discarding   
of1 or risk of injury to1 a human       
embryo4  #c4 ,human stem cell research  
and therapy  7a7 ,authorization ,part ,b
 of title ,,iv of the ,public ,health   
,service ,act 7#db ,u4,s4,c4 #bhd et    
seq47 is amended by inserting after     
section #dji;,i the following3  #dji,k4 
,human stem cell research and therapy   
7a7 ,in general ,the ,secretary shall   
conduct and support basic and applied   
research to develop techniques for the  
isolation1 derivation1 production1      
testing1 and human clinical use of stem 
cells that may result in improved       
understanding of or treatments for      
diseases and other adverse health       
conditions1 including pluripotent stem  
cells that have the flexibility of      
embryonic stem cells 7whether or not    
such pluripotent stem cells have an     
embryonic source71 prioritizing research
 with the greatest potential for        
near-term clinical benefit in human     
patients1 provided that such isolation1 

derivation1 production1 testing1 or use 
will not involve-- 7#a7 the creation of 
a human embryo for research purposes2   
7#b7 the destruction of or discarding   
of1 or risk of injury to1 a living human
 embryo2 or  7#c7 the use of any stem   
cell1 the derivation or provision of    
which would be inconsistent with the    
standards established in paragraph 7#a7 
or 7#b74  7b7 ,guidelines ,not later    
than #ij days after the date of the     
enactment of this section1 the          
,secretary1 after consultation with the 
,director of ,,nih1 shall issue final   
guidelines implementing subsection 7a7  
to ensure that any research 7including  
any clinical trial7 supported under     
subsection 7a7-- 7#a7 is clearly        
consistent with the standards           
established in subsection 7a7 if        
conducted using human cells1 as         
demonstrated by animal trials or other  
substantial evidence2 and  7#b7 is      
prioritized in terms of potential for   
near-term clinical benefit in human     

patients1 as indicated by substantial   
evidence from basic research or by      
substantial clinical evidence which may 
include but is not limited to-- 7,a7    
evidence of improvement in one or more  
human patients suffering from illness or
 injury1 as documented in reports by    
professional medical or scientific      
associations or in peer-reviewed medical
 or scientific literature2 or  7,b7     
approval for use in human trials by the 
,food and ,drug ,administration4  7c7   
,definitions ,in this section3  7#a7    
,human embryo ,the term human embryo    
includes any organism1 not protected as 
a human subject under part #df of title 
#de1 ,code of ,federal ,regulations1 as 
of the date of the enactment of this    
section1 that is derived by             
fertilization1 parthenogenesis1 cloning1
 or any other means from one or more    
human gametes or human diploid cells4   
7#b7 ,risk of injury ,the term risk of  
injury means subjecting a human embryo  
to risk of injury or death greater than 

that allowed for research on fetuses in 
utero under section #df4bjd7;b7 of title
 #de1 ,code of ,federal ,regulations 7or
 any successor regulation71 or section  
#dih7;b7 of this ,act4  4  7b7 ,priority
 setting2 reports ,section #dib of the  
,public ,health ,service ,act 7#db      
,u4,s4,c4 #bhi;a7 is amended by adding  
at the end the following3  7d7 7#a7     
,with respect to human stem cell        
research1 the ,secretary1 acting through
 the ,director of ,,nih1 shall give     
priority to conducting or supporting    
research in accordance with section     
#dji,k4  7#b7 ,at the end of fiscal year
 #bjaf and each subsequent fiscal year1 
the ,secretary shall submit to the      
,congress a report outlining the number 
of research proposals under section     
#dji,k that were peer reviewed1 a       
summary and detailed list of all such   
research proposals that were not funded1
 and an explanation of why the proposals
 did not merit funding4 ,the reports    
under this paragraph shall be in        

addition to the reporting on stem cell  
research included in the biennial report
 required by section #djc4  4  7c7      
,biennial reports ,section #djc7;a77#e7 
of the ,public ,health ,service ,act    
7#db ,u4,s4,c4 #bhc7;a77#e77 is         
amended--  7#a7 by redesignating        
subparagraph 7,l7 as subparagraph 7,m72 
and  7#b7 by inserting after            
subparagraph 7,k7 the following3  7,l7  
,stem cells4  4